"A calm, soothing environment has been created in the heart of the Fort Worth medical district to help smooth the path for you or your loved one’s cancer treatment journey. With the focus on healing lives and advancing care, our Central Campus building was designed to provide one familiar location for practically all cancer treatment services. Offering you the finest technology in the nation, all at a single location, eliminates the hassle often associated with complex medical care."

During the past decade, The Center for Cancer and Blood Disorders conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 69 clinical trials were completed, i.e. on average, 106.2% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 38 clinical trials were completed. i.e. 165.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Center for Cancer and Blood Disorders" #1 sponsor was "SCRI Development Innovations, LLC" with 19 trials, followed by "Eli Lilly and Company" with 10 trials sponsored, "Hoffmann-La Roche" with 10 trials sponsored, "Novartis Pharmaceuticals" with 8 trials sponsored and "Bristol-Myers Squibb" with 8 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Center for Cancer and Blood Disorders" #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Celgene" with 3 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator and "Novartis" with 3 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "The Center for Cancer and Blood Disorders" are "Breast Cancer" (17 trials), "Metastatic Breast Cancer" (9 trials), "Bladder Cancer" (5 trials), "Colorectal Cancer" (4 trials) and "Breast Neoplasms" (3 trials). Many other conditions were trialed in "The Center for Cancer and Blood Disorders" in a lesser frequency.

Most popular intervention types in "The Center for Cancer and Blood Disorders" are "Drug" (108 trials), "Biological" (8 trials), "Other" (6 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (15 trials), "Placebo" (15 trials), "Docetaxel" (13 trials), "Trastuzumab" (9 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "The Center for Cancer and Blood Disorders" are 89 trials for "All" genders, 20 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "The Center for Cancer and Blood Disorders". undefined are not yet recruiting, 15 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 61 completed trials in The Center for Cancer and Blood Disorders, undefined suspended trials, and 23 terminated clinical trials to date.

Out of the total trials that were conducted in The Center for Cancer and Blood Disorders, 5 "Phase 1" clinical trials were conducted, 59 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".

The Center for Cancer and Blood Disorders has several departments that took part in Clinical trials: "The Center for Cancer and Blood Disorders" - 5 trials, "Southlake Oncology" - 4 trials, "SCRI The Center For Cancer and Blood Disorders" - 2 trials, "The Center for Cancer and Blood Disorders-Mineral Wells" - 2 trials, "The Center for Cancer and Blood Disorders-Burleson" - 2 trials